Avoralstat

Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research[1][2].

Product Specifications

CAS Number

[918407-35-9]

Product Name Alternative

BCX4161

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Kallikrein

Type

Reference compound

Related Pathways

Immunology/Inflammation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/Avoralstat.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=NC(C(NCC2CC2)=O)=CC=C1C3=CC(OC)=C(C=C)C=C3C(NC4=CC=C(C(N)=N)C=C4)=O)O

Molecular Formula

C28H27N5O5

Molecular Weight

513.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Aygoren-Pursun E, et al. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. J Allergy Clin Immunol. 2016 Sep;138 (3) :934-936.e5.|[2]Cornpropst M, et al. Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study. Allergy. 2016;71 (12) :1676-1683.